Next Article in Journal
Nicotine in E-Cigarettes Dysregulates Pulmonary Inflammation and MMP-12 Expression without Effecting Respiratory Syncytial Virus Virulence
Previous Article in Journal
SARS-CoV-2 Spike Protein and Lung Vascular Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoR
Volume 1
Issue 1
10.3390/jor1010005
jor-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities

by
Selvakumar Subbian
Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA
J. Respir. 2021, 1(1), 49-59; https://doi.org/10.3390/jor1010005
Submission received: 21 December 2020 / Revised: 6 January 2021 / Accepted: 7 January 2021 / Published: 12 January 2021
Browse Figure
Versions Notes

Abstract

:
The Coronavirus Disease-2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has claimed 1.2 million people globally since December 2019. Although the host factors underpinning COVID-19 pathology are not fully understood, type I interferon (IFN-I) response is considered crucial for SARS-CoV-2 pathogenesis. Perturbations in IFN-I signaling and associated interferon-inducible genes (ISG) are among the primary disease severity indicators in COVID-19. Consequently, IFN-I therapy, either alone or in- combination with existing antiviral or anti-inflammatory drugs, is tested in many ongoing clinical trials to reduce COVID-19 mortality. Since signaling by the IFN-I family of molecules regulates host immune response to other infectious and non-infectious diseases, any imbalance in this family of cytokines would impact the clinical outcome of COVID-19, as well as other co-existing diseases. Therefore, it is imperative to evaluate the beneficial-versus-detrimental effects of IFN-I immunotherapy for COVID-19 patients with divergent disease severity and other co-existing conditions. This review article summarizes the role of IFN-I signaling in infectious and non-infectious diseases of humans. It highlights the precautionary measures to be considered before administering IFN-I to COVID-19 patients having other co-existing disorders. Finally, suggestions are proposed to improve IFN-I immunotherapy to COVID-19.

1. Introduction

The highly contagious Coronavirus Disease-2019 (COVID-19) is caused by a novel, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is thought to be a “spill-over” from bats to humans occurred in Wuhan, China, during December 2019. The infection spread very rapidly to the rest of the world, and the World Health Organization (WHO) declared COVID-19 as a global pandemic on 11 March 2020.
As of 8 January 2021, there were about 86 million confirmed COVID-19 cases and over 1.8 million deaths reported worldwide, with numbers steadily rising every day [1]. In the absence of any proven vaccine and/or targeted therapeutic agent available, COVID-19 cases are currently treated empirically, based on the disease symptoms. Several clinical trials are ongoing for COVID-19 therapy, including antiviral agents, antibodies against inflammatory cytokines, and repurposing of drugs used for other ailments [2]. There are currently at least 60 clinical trials at various stages of implementation to determine the beneficial effects of type I interferon (IFN-I) (α, β, or both), either alone or in-combination with antiviral or anti-inflammatory drugs, in reducing COVID-19 mortality [3]. However, the implied beneficial effects of IFN-I therapy in these clinical trials could be confounded by the broad immune-regulatory functions elicited by this family of cytokines.

2. Type-I IFN Signaling

The interferon (IFN) family of cytokines is broadly classified into type I, II, and III. The IFN-I consists of 13 subtypes, including IFNα, β, κ, ε, ω, and τ, all of which bind to the interferon-alpha receptor complex (IFNAR), composed of the IFNARI and IFNARII chains (Figure 1). Plasmacytoid dendritic cells (DC) are the primary producers of IFNα, and binding of IFNα to IFNAR activates the JAK-STAT signaling pathway that induces interferon-stimulated genes (ISGs) [4]. Together, the JAK-STAT pathway and ISG molecules play crucial roles in the host immune response to bacterial, viral, and fungal diseases and associated inflammation [4]. Pathogen recognition by phagocytes through pathogen-associated molecular patterns (PAMPs) activates multiple and divergent host immune response signaling networks, including the IFN-I response pathways. Subsequent induction of downstream ISGs through the IFN-I pathway facilitates efficient viral killing and controls inflammation. During SARS-CoV-2 infection, the host cytoplasmic molecules, such as retinoic acid-inducible gene-1 (RIG-1) and melanoma differentiation-associated gene-5 (MDA5), recognize intracellular viral RNA and activate the IFN-I pathway, which ultimately enhances the production of effector molecules such as ISGs. Since ISGs regulate a vast range of cellular functions, ranging from transcription to translation of proinflammatory and metabolic molecules in phagocytic cells, any impairment in IFN-I signaling can be harmful to the host. Thus, optimal and timely activation of IFN-I signaling is crucial for a well-coordinated antiviral effect of phagocytes with minimal damage to the host [1,2,3,4].
Apart from ISGs, IFN-I augments host protection against viral infections by recruiting and activating innate (DC, natural killer (NK) cells, neutrophils, monocytes, and macrophages) and adaptive (T and B) immune cells [5,6].

3. Type-I IFN Response and IFN-I Immunotherapy for COVID-19

The IFN-I pathway also plays a central role in the pathogenesis of COVID-19 [4]. Perturbations in IFN-I and ISG levels are among the primary indicators of disease severity in COVID-19 cases. A significant reduction in serum IFN-I levels has been reported in critically ill COVID-19 patients with a high viral load in their respiratory tract than those with mild or moderate disease symptoms. Consistently, the number of plasmacytoid DC, the primary producers of IFNα, was reduced in patients with severe COVID-19, contributing to reduced IFN-I levels. However, data from SARS-CoV-2 infection studies conducted on lung epithelial cells expressing angiotensin-converting enzyme-2 (ACE2) receptor, as well as in human organoids, human bronchial cells, and in post-mortem lung samples of COVID-19 cases showed, a moderate-to-high level of ISGs (e.g., MX1, MX2, OAS1, IFI6, IFI27, IFIT1, IFIT3, IFITM1, IFITM2, and IFITM3) despite a low-to-undetectable IFN-I level. This observation suggests that either the infected host cells are refractory to the COVID-19 defense mechanism or the uninfected cells also contribute to elevated ISG level (bystander effect).
Induction of ISGs in infected cells mounts a robust antiviral response against SARS-CoV-2, including blocking viral replication. Besides, upregulation of ISGs, such as IFIT and IFITM family genes, including OASL, OAS2, IFI6, MX1, and MX2, as well as proinflammatory cytokines, including IL-1β IL-10, TNF-α, IL-6, and IL-1Ra was noted in the bronchoalveolar lavage fluid of COVID-19 patients [7,8,9]. The expression level of several proinflammatory genes involved in IFN-I signaling, including MX1, STAT1, STAT2, IFITM1, IFIT2, IFI35, IFIH1, IRF7, and IFI16 was enriched in COVID-19 patients [10]. Furthermore, these molecules’ expression patterns could differentiate mild/moderate COVID-19 cases from healthy individuals [10]. However, due to the complexity of the inflammatory cascade associated with COVID-19 pathogenesis and the heterogeneity in disease presentation, it is challenging to associate specific inflammatory molecules’ gene expression patterns as surrogates to determine the mortality index of a given patient. Given the limited number of patient samples used in gene expression studies, it is premature to conclusively define biomarkers of disease severity in COVID-19, based purely on the expression pattern of a specific set of genes. Thus, extensive profiling of enriched inflammatory gene expression from different clinical samples of many patients with various disease severity is required to define and correlate biomarkers with corresponding prognoses of COVID-19 cases. A recent study on the transcriptome of lung epithelial cells and the pulmonary granulomas of non-human primates reported that ACE2, the primary receptor for SARS-CoV-2 entry into host cells, is also a member of ISG. This study also indicated a dual role for IFN-specific upregulation of ACE2 in tissue tolerance and infection upon SARS-CoV-2 entry into host cells [11]. Although induction of ISGs contributes to host cells’ antiviral effects against SARS-CoV-2, the mechanistic link between IFN-I, ISG, and ACE2 pathways and associated regulation of host immune response in COVID-19 remains unknown.
Comorbidities and genetic susceptibility of the host can also alter the IFN-I response to viral infections and cause detrimental effects to the host [10]. During the initial stages of COVID-19, when the viral load, disease severity, and antibody responses are low, IFN-I plays a beneficial host effect by inhibiting viral propagation in the host. Consistently, elevated levels of IFN-I were observed at the infection site and in the blood of COVID-19 cases with mild symptoms and low viral burden. Thus, elevated IFN-I appears to be a host response against SARS-CoV-2 replication, dampening inflammation and alleviating disease symptoms. However, in COVID-19 patients with severe disease symptoms and a higher viral load, including the elderly population and those with comorbid conditions, the expression of IFN-I was significantly suppressed and was associated with exacerbated tissue inflammation and disease pathology [12]. Notably, the causal link between the level of IFN-I in the host and the severity of COVID-19 remains unknown. Similarly, the network/pathway regulating IFN-I-mediated antiviral and anti-inflammatory activities during COVID-19-mediated tissue damage is yet to be determined.
Several IFN-I subtypes, particularly IFN-α and IFN-β, are currently evaluated in several clinical trials for their therapeutic potential in controlling COVID-19 (Table 1). The rationale for IFN-I therapy is that compensating for the loss of IFN-I during SARS-CoV-2 would aid in viral clearance and alleviate inflammation associated with the disease severity among COVID-19 cases. However, in light of its dual and opposing role of IFN-I in COVID-19 pathogenesis, the use of IFN-I treatment should be carefully considered. Most of these clinical studies are either recruiting or yet to recruit patients for evaluating the beneficial effect of various IFN-I immunotherapy against COVID-19. Availability of data from these trials would inform about the efficacy of each of these IFN-I sub-types and factors impacting IFN-I immunotherapy for COVID-19 cases in the future.

4. Implications of IFN-I Immunotherapy on the Host Response to Other Infectious Diseases

Below is a summary of health conditions in which IFN-I immunotherapy can potentially impact the host response to bacterial and viral infections and the clinical outcome of treatment.

4.1. Viral Diseases

IFN therapy has been credited as prophylaxis to prevent virus-induced exacerbations in airway diseases, such as chronic obstructive pulmonary disease (COPD). A recent report using the primary cell culture model of respiratory syncytial virus (RSV) and influenza virus infection shows that intermittent treatment with IFN-β was beneficial to the host cells and did not trigger proinflammatory cytokines, such as IL-1β, TNF, and IL-6 [13]. This observation suggests that IFN-I therapy helps to prevent COVID-19-associated pulmonary exacerbations in patients with pre-existing COPD or co-infected with other viral pathogens such as RSV.
The role of IFN-I in human immunodeficiency virus (HIV) infection and its therapeutic role is inconclusive. Upon the entry of HIV-1, the pathogen recognition receptors (PRR) on phagocytes, including Toll-like receptor-7 (TLR7), cGAS, and IFI16, recognize the viral antigens and secrete IFN-I. Binding of IFN-I to IFNAR and phosphorylation of the downstream JAK/STAT pathway leads to the upregulation of ISGs, which are proven antiviral defense molecules (Figure 1). Since the induction of ISGs can deplete CD4+ and CD8+ cells, a low level of IFN-I during the early stages of HIV-1 infection was presumed beneficial. Thus, a delayed and/or sub-optimal IFN-I production can lead to an immunosuppressive niche and persistent, chronic disease. However, during latent HIV-1 infection, sustained IFN-I signaling is associated with immune activation and viral persistence. In summary, IFN-I signaling has a paradoxical yet dynamic role in the pathogenesis of acute vs. chronic/persistent HIV-1 infection [14,15]. Hence, caution should be taken when administering IFN-I treatment to COVID-19 patients who are also HIV-positive. Clinical parameters, such as blood CD4+ T cell counts and co-infection with other pathogens, should be monitored in these patients during IFN therapy.

4.2. Nosocomial Infection

Reports have shown that COVID-19 cases acquire secondary nosocomial infections, including multidrug-resistant Staphylococcus aureus and Streptococcus pneumonia, possibly due to lower IFN-I levels in these patients. However, excessive IFN-I levels have been associated with increased susceptibility to disease progression with worsened pneumonia. Moreover, elevated IFN-I molecules inhibit the proinflammatory TH17 signaling and impair the recruitment of macrophages and neutrophils, as well as neutrophil chemokine secretion, all of which facilitate the progression of nosocomial infection [16]. However, the correlation between IFN-I levels and disease severity in COVID-19 or secondary nosocomial infections is not fully understood. Since critically ill COVID-19 patients in hospitals are more prone to nosocomial infections, the dose and route of administration of IFN-I and therapy duration should be planned cautiously.

4.3. Tuberculosis

Upregulation of IFN-I pathway molecules has been reported during infection by Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), a contagious bacterial disease marked by severe, chronic lung inflammation [17]. TB, primarily a pulmonary disease, caused 1.5 million deaths worldwide and an estimated 10 million new cases in 2018 (https://www.who.int/tb/publications/factsheet_global.pdf?ua=1). Elevated IFN-I levels correlate with the disease severity caused by hypervirulent Mtb strains and increased host susceptibility to active TB. Several possible mechanisms, including suppression of proinflammatory innate and Th1 responses, early cell death of alveolar macrophages, recruitment of permissive myeloid cells, and the reduced macrophage antibacterial responses, are associated with the detrimental effect of elevated IFN-I in Mtb-infected host [17]. However, when co-administered with anti-mycobacterial therapy or Bacille Calmette-Guerin (BCG) vaccine, IFN-α conferred host-protective effect against Mtb infection. Studies using human PBMCs and animal models showed that priming with IFN-α increases the BCG vaccine’s efficacy and promotes T-cell priming and IFN-γ-induced production of “host-protective” proinflammatory cytokines, including IL-12, TNF-α, IL-17, and IL1β [18]. Notably, the role of IFN-I in regulating chronic, asymptomatic latent Mtb infection (LTBI) and their potential for reactivating LTBI to active TB disease remains unclear. Thus, IFN-I treatment of COVID-19 cases with underlying LTBI might lead to TB reactivation. Moreover, patients with symptomatic, active TB have elevated IFN-I levels [17]. Therefore, in the context of Mtb infection, the effect of IFN-I response can be beneficial or detrimental to the host, dependent on whether the host is immunized with BCG or having LTBI/active TB, respectively. In this regard, measuring the IFN-I level in samples, and TB or LTBI status of the patient, determined by skin test or quantiferon test or chest X-ray, would be valuable for initiating IFN therapy for COVID-19 cases. This approach would alleviate the risk for reactivation of LTBI or exacerbation of TB among COVID-19 patients.

5. Implications of IFN-I Immunotherapy on the Host Response to Non-infectious Diseases

5.1. Pulmonary Arterial Hypertension

IFN-I therapy-induced pulmonary arterial hypertension (PAH) has been reported in both experimental models and human clinical studies [19]. PAH is also associated with IFNα therapy of cancer and hepatitis C cases and IFNβ therapy of multiple sclerosis (MS) patients. However, clinical data for the reversal of IFN therapy-induced PAH, either spontaneously or after treatment with a phosphodiesterase-5 (PDE5) inhibitor for PAH therapy, is inconclusive. Some predispositions, such as HIV infection, impose an additional risk for PAH, either by indirect mechanism(s) or by releasing inflammatory mediators and growth factors [19].

5.2. Diabetes

The destruction of the β-cell mass by the host immune response augments type 1 diabetes mellitus (DM) associated with increased MHC class I expression and elevated cytotoxic CD8+ T cells after β-cell antigen-specific T-cell receptors interaction with MHC peptide complexes. Interestingly, IFN-I molecules, through binding to IFNARI and II, activates JAK1/TYK2 kinases. The STAT1/2 signaling influences both the pathway as mentioned above—MHC class I expression and cytotoxic CD8+ cells infiltration through IRF9 and STAT4. Besides, IFN-I, through its downstream signaling molecules, notably CXCL10, a prominent ISG involved in the inflammatory response, achieves its diabetic milieu within the β-pancreatic cells through TLR4 signaling. Furthermore, IFNα/β treatment is implicated in the onset of acute type 1 DM, and extreme caution and careful monitoring are required when IFN-I is administered for COVID patients with DM. Since type II DM is a common comorbid condition to COVID-19, cautious follow-up of patients is essential to identify those suitable for IFN-I therapy [20,21,22].

5.3. Autoimmune Diseases

IFN-I is implicated in the pathogenesis of autoimmune connective tissue diseases, such as systemic lupus erythematosus (SLE), polyendocrinopathy syndrome, and inflammatory myositis [23]. Antibodies that bind to IFNs are considered as a therapeutic intervention in those diseases. However, the protective versus the detrimental role of IFN-I is dependent on the time of infection or disease state (early versus chronic) and the magnitude of the host response to an infectious agent or severity of disease (mild/moderate versus severe). Therefore, therapeutic approaches using IFN antibodies should consider risk factors, including comorbidities such as HIV, DM, hypertension, respiratory airway diseases, and genetic predisposition, all of which can affect COVID-19 prognosis. Moreover, autoantibodies to IFN-I have been reported in the sera of patients with rheumatologic diseases. Interestingly, these autoantibodies mimic the IFN-I in stimulating the human endothelial cells and activating the downstream pathways that ultimately elevated the expression of IRGs [24,25]. A recent multicenter study shows that about 10% of the 987 COVID-19 patients with severe disease had neutralizing IgG auto-antibodies against IFN-I in the plasma/serum. Notably, the development of autoantibodies against IFN-I appears to be associated with the severity of COVID-19, as mild or symptomatic cases failed to show these autoantibodies [26].

6. Summary and Conclusions

With the plethora of clinical manifestations regulated by the IFN-I signaling pathway, extreme vigilance is required to achieve a beneficial effect in using this immune modulatory molecule as a target for COVID-19 treatment. Since the induction of IFN-I is useful during the early stages of infection, the same can be harmful when the infection progresses into fulminant COVID-19; thus, the initiation time of IFN-I immunotherapy is among the crucial factors in enhancing the host response against SARS-CoV-2 infection. Testing for co-existing conditions, such as LTBI, chronic obstructive pulmonary disease (COPD), type II diabetes mellitus (T2DM), or HIV infection, should be mandated before starting anti-IFN-I therapy for COVID-19 cases since the immunotherapy can potentially worsen those ailments. It is also intriguing to investigate whether TB and/or HIV positive patients on anti-IFN-I therapy combined with anti-mycobacterial and/or anti-retroviral drugs have added advantage of protection against the progression of SARS-CoV-2 infection. It is also worth investigating the beneficial effect of IFN-I as an adjunct to other immunomodulatory agents, such as vitamin D, which is a crucial factor in regulating the host response to infectious diseases, including COVID-19 [27]. Such critical investigations should be tested in a “relevant-to-human” preclinical animal model of pulmonary SARS-CoV-2 infection, such as non-human primates, ferrets, and hamsters that recapitulate the most pathophysiology seen in patients with COVID-19 [28]. Besides, clinical data obtained through ongoing trials (Table 1) should guide to fine-tune the therapeutic value of IFN-I for the treatment of COVID-19 by informing about factors such as the route, dosing, and form of IFN-I administration, and monitoring for other associated disease conditions.

Funding

The author received a grant from the Center for COVID-19 Response and Pandemic Preparedness (CCRP2) of The Rutgers University (Project#302211).

Acknowledgments

The author sincerely acknowledges Radha Gopalaswamy for the critical analysis of this manuscript. Natarajan Ganesan is acknowledged for helpful discussions on the subject matter.

Conflicts of Interest

The author declares no conflict of Interest.

References

  1. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 8 January 2021).
  2. Khalaf, K.; Papp, N.; Chou, J.T.; Hana, D.; Mackiewicz, A.; Kaczmarek, M. SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. Front. Immunol. 2020, 11, 570927. [Google Scholar] [CrossRef]
  3. U.S. National Library of Medicine. Clinical Trials–COVID19. Available online: https://www.clinicaltrials.gov/ct2/results?cond=COVID-19 (accessed on 7 November 2020).
  4. McNab, F.; Mayer-Barber, K.; Sher, A.; Wack, A.; O’Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 2015, 15, 87–103. [Google Scholar] [CrossRef] [PubMed]
  5. Lee, A.J.; Ashkar, A.A. The Dual Nature of Type I and Type II Interferons. Front. Immunol. 2018, 9, 2061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Teijaro, J.R. Pleiotropic Roles of Type 1 Interferons in Antiviral Immune Responses. Adv. Immunol. 2016, 132, 135–158. [Google Scholar] [PubMed]
  7. Sa Ribero, M.; Jouvenet, N.; Dreux, M.; Nisole, S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020, 16, e1008737. [Google Scholar] [CrossRef] [PubMed]
  8. Zhou, R.; To, K.K.; Wong, Y.C.; Liu, L.; Zhou, B.; Li, X.; Huang, H.; Mo, Y.; Luk, T.Y.; Lau, T.T.; et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity 2020, 53, 864–877.e5. [Google Scholar] [CrossRef]
  9. Zhou, Z.; Ren, L.; Zhang, L.; Zhong, J.; Xiao, Y.; Jia, Z.; Guo, L.; Yang, J.; Wang, C.; Jiang, S.; et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe 2020, 27, 883–890.e2. [Google Scholar] [CrossRef]
  10. Hadjadj, J.; Yatim, N.; Barnabei, L.; Corneau, A.; Boussier, J.; Smith, N.; Pere, H.; Charbit, B.; Bondet, V.; Chenevier-Gobeaux, C.; et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020, 369, 718–724. [Google Scholar] [CrossRef]
  11. Ziegler, C.G.K.; Allon, S.J.; Nyquist, S.K.; Mbano, I.M.; Miao, V.N.; Tzouanas, C.N.; Cao, Y.; Yousif, A.S.; Bals, J.; Hauser, B.M.; et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell 2020, 181, 1016–1035.e19. [Google Scholar] [CrossRef]
  12. Park, A.; Iwasaki, A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe 2020, 27, 870–878. [Google Scholar] [CrossRef]
  13. Johnston, S.L. IFN Therapy in Airway Disease: Is Prophylaxis a New Approach in Exacerbation Prevention? Am. J. Respir. Crit. Care Med. 2020, 201, 9–11. [Google Scholar] [CrossRef] [PubMed]
  14. Scagnolari, C.; Antonelli, G. Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome. Cytokine Growth Factor Rev. 2018, 40, 19–31. [Google Scholar] [CrossRef] [PubMed]
  15. Sugawara, S.; Thomas, D.L.; Balagopal, A. HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters. AIDS Res. Hum. Retroviruses 2019, 35, 25–32. [Google Scholar] [CrossRef] [PubMed]
  16. Parker, D. Impact of Type I and III Interferons on Respiratory Superinfections Due to Multidrug-Resistant Pathogens. J. Infect. Dis. 2017, 215, S58–S63. [Google Scholar] [CrossRef] [Green Version]
  17. Moreira-Teixeira, L.; Mayer-Barber, K.; Sher, A.; O’Garra, A. Type I interferons in tuberculosis: Foe and occasionally friend. J. Exp. Med. 2018, 215, 1273–1285. [Google Scholar] [CrossRef] [Green Version]
  18. Rivas-Santiago, C.E.; Guerrero, G.G. IFN-alpha Boosting of Mycobacterium bovis Bacillus Calmette Guerin-Vaccine Pro-moted Th1 Type Cellular Response and Protection against M. tuberculosis Infection. Biomed. Res. Int. 2017, 2017, 8796760. [Google Scholar] [CrossRef]
  19. Savale, L.; Chaumais, M.C.; O’Connell, C.; Humbert, M.; Sitbon, O. Interferon-induced pulmonary hypertension: An update. Curr. Opin. Pulm. Med. 2016, 22, 415–420. [Google Scholar] [CrossRef]
  20. Nakamura, K.; Kawasaki, E.; Imagawa, A.; Awata, T.; Ikegami, H.; Uchigata, Y.; Kobayashi, T.; Shimada, A.; Nakanishi, K.; Makino, H.; et al. Type 1 diabetes and interferon therapy: A nationwide survey in Japan. Diabetes Care 2011, 34, 2084–2089. [Google Scholar] [CrossRef] [Green Version]
  21. Newby, B.N.; Mathews, C.E. Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front. Endocrinol. (Lausanne) 2017, 8, 232. [Google Scholar] [CrossRef] [Green Version]
  22. Schulthess, F.T.; Paroni, F.; Sauter, N.S.; Shu, L.; Ribaux, P.; Haataja, L.; Strieter, R.M.; Oberholzer, J.; King, C.C.; Maedler, K. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 2009, 9, 125–139. [Google Scholar] [CrossRef] [Green Version]
  23. Psarras, A.; Emery, P.; Vital, E.M. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford) 2017, 56, 1662–1675. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Gupta, S.; Tatouli, I.P.; Rosen, L.B.; Hasni, S.; Alevizos, I.; Manna, Z.G.; Rivera, J.; Jiang, C.; Siegel, R.M.; Holland, S.M.; et al. Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases. Arthritis Rheumatol. 2016, 68, 1677–1687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Moll, H.P.; Freudenthaler, H.; Zommer, A.; Buchberger, E.; Brostjan, C. Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells. J. Immunol. 2008, 180, 5250–5256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Bastard, P.; Rosen, L.B.; Zhang, Q.; Michailidis, E.; Hoffmann, H.H.; Zhang, Y.; Dorgham, K.; Philippot, Q.; Rosain, J.; Beziat, V.; et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020, 370, eabd4585. [Google Scholar] [CrossRef] [PubMed]
  27. Murdaca, G.; Pioggia, G.; Negrini, S. Vitamin D and Covid-19: An update on evidence and potential therapeutic implications. Clin. Mol. Allergy 2020, 18, 23. [Google Scholar] [CrossRef]
  28. Munoz-Fontela, C.; Dowling, W.E.; Funnell, S.G.P.; Gsell, P.S.; Riveros-Balta, A.X.; Albrecht, R.A.; Andersen, H.; Baric, R.S.; Carroll, M.W.; Cavaleri, M.; et al. Animal models for COVID-19. Nature 2020, 586, 509–515. [Google Scholar] [CrossRef]
Jor 01 00005 g001 550
Figure 1. Canonical type I interferon signaling. IFN-I family of cytokines, encompassing IFN-α, -β, and –κ play critical roles in initiating, maintaining, and regulating host immune responses, particularly against viral infections [5,6]. The IFN signaling starts with type I and II IFN receptors (IFNR), which are transmembrane proteins that function as heterodimers. While type I IFNR comprises AR1 and AR2 subunits, type II IFNR is made of GR1 and GR2. The IFNAR1 and IFNGR1 are involved in binding type I and type II IFNs, respectively, while IFNAR2 and IFNGR2 subunits are involved in signal transduction. Engagement of IFNAR2 and IFNGR2 activates tyrosine kinases JAK1, JAK2, and TYK2 that phosphorylate the STAT1 and 2 proteins. After dimerization, the STAT proteins translocate to the nucleus. In the case to type I IFNs, the STAT1/2 heterodimers associate with IFN gene regulatory factor-9 (IRF-9), forming ISGF3, a trimeric transcription factor. The vitamin D receptor-interacting protein150 (DRIP150) interacts with STAT2 and stimulates IFN-dependent transcription. ISGF3 and DRIP150 complex bind to the IFN-stimulated regulatory elements (ISREs) to induce the expression of several IFN-α/β-regulated genes [5,6]. Abbreviations: TYK2—tyrosine kinase 2; JAK1—Janus kinase 1; TC-PTP—T-cell protein tyrosine phosphatase; STAT—signal transducer and activator of transcription; IFI—interferon-induced protein; DRIP150—vitamin D receptor-interacting protein 150; IRF—interferon regulatory factor; PSMB—proteasome 20S subunit beta; IFIT—interferon-induced protein with tetratricopeptide repeats; OAS—O-acetyl serine; MX1—MX dynamin-like GTPase 1; G1P2—ISG-15 ubiquitin-like modifier; ISRE—interferon-stimulated response element.
Figure 1. Canonical type I interferon signaling. IFN-I family of cytokines, encompassing IFN-α, -β, and –κ play critical roles in initiating, maintaining, and regulating host immune responses, particularly against viral infections [5,6]. The IFN signaling starts with type I and II IFN receptors (IFNR), which are transmembrane proteins that function as heterodimers. While type I IFNR comprises AR1 and AR2 subunits, type II IFNR is made of GR1 and GR2. The IFNAR1 and IFNGR1 are involved in binding type I and type II IFNs, respectively, while IFNAR2 and IFNGR2 subunits are involved in signal transduction. Engagement of IFNAR2 and IFNGR2 activates tyrosine kinases JAK1, JAK2, and TYK2 that phosphorylate the STAT1 and 2 proteins. After dimerization, the STAT proteins translocate to the nucleus. In the case to type I IFNs, the STAT1/2 heterodimers associate with IFN gene regulatory factor-9 (IRF-9), forming ISGF3, a trimeric transcription factor. The vitamin D receptor-interacting protein150 (DRIP150) interacts with STAT2 and stimulates IFN-dependent transcription. ISGF3 and DRIP150 complex bind to the IFN-stimulated regulatory elements (ISREs) to induce the expression of several IFN-α/β-regulated genes [5,6]. Abbreviations: TYK2—tyrosine kinase 2; JAK1—Janus kinase 1; TC-PTP—T-cell protein tyrosine phosphatase; STAT—signal transducer and activator of transcription; IFI—interferon-induced protein; DRIP150—vitamin D receptor-interacting protein 150; IRF—interferon regulatory factor; PSMB—proteasome 20S subunit beta; IFIT—interferon-induced protein with tetratricopeptide repeats; OAS—O-acetyl serine; MX1—MX dynamin-like GTPase 1; G1P2—ISG-15 ubiquitin-like modifier; ISRE—interferon-stimulated response element.
Jor 01 00005 g001
Table
Table 1. Description of various clinical trials testing IFN-I therapy for COVID-19 $.
Table 1. Description of various clinical trials testing IFN-I therapy for COVID-19 $.
Trial IDIFN-I MoleculeAdjunctive Drug #Route of IFN-I AdministrationStudy SponsorReference/Status *
ChiCTR2000029387IFNα1βLopinavir/Ritonavir or Ribavirin SubcutaneousChongqing Public Health Medical Center, ChinaRecruiting
ChiCTR2000029638IFNα (“super-compound”)Umifenovir or Lopinavir and RitonavirNebulizationWest China Hospital, ChinaRecruiting
ChiCTR2000030262IFNκTrefoil Factor Family 2Aerosol inhalationShanghai Medical College, ChinaRecruiting
ChiCTR2000030013IFNα1βStandard careNasal sprayChinese PLA General Hospital, ChinaNot recruiting
ChiCTR2000030166IFNα2βLopinavir/Ritonavir or Qing-Wen Bai-Du-Yin granulesInjection (route not disclosed)The 5th Medical Center Chinese PLA General Hospital, ChinaNot recruiting
ChiCTR2000030922IFNα2αRibavirinRoute not disclosedFoshan First People’s Hospital, ChinaRecruiting
ChiCTR2000029989IFNα1βStandard careEye dropsChinese PLA General Hospital, ChinaNot recruiting
ChiCTR2000030082IFNαDihydroartemisinin/Piperaquine or ArdibdolRoute not disclosedThe First Affiliated Hospital of Nanchang University, ChinaSuspended
ChiCTR2000029600IFNαLopinavir/Ritonavir or FavipiravirAtomization (nasal spray)The Third People’s Hospital of Shenzhen, ChinaRecruiting
ChiCTR2000030535IFNαEbastine and LopinavirAerosol inhalationMianyang Central Hospital, ChinaRecruiting
IRCT20100228003449N27IFNβ1αHydroxychloroquine, Lopinavir/RitonavirSubcutaneousTehran University of Medical Sciences, IranRecruiting
IRCT20100228003449N28IFNβ1αHydroxychloroquine, lopinavir/ritonavirSubcutaneousTehran University of Medical Sciences, IranRecruiting
2020-001023-14IFNβ1αStandard careAerosol inhalationSynairgen Ltd., United KingdomRecruiting
2020-001113-21 (RECOVERY Trial)IFNβ1αStandard careAerosol inhalationUniversity of Oxford, United KingdomRecruiting
2020-000936-23 (DisCoVeRy Trial)IFNβ1αStandard careSubcutaneousINSERM, FranceRecruiting
NCT04315948 (DisCoVeRy Trial)IFNβ1αLopinavir/Ritonavir or Standard careSubcutaneousInstitut National de la Sante Et de la Recherche Medicale, FranceRecruiting
NCT04276688IFNβ1βLopinavir/Ritonavir, RibavirinSubcutaneousThe University of Hong Kong, Hong Kong.Recruitment completed
NCT04254874IFNα2βAbidol hydrochlorideAtomization (nasal spray)Tongji Hospital, ChinaRecruiting
NCT04293887IFNα1βLopinavir/Ritonavir, RemdesivirNebulization inhalationTongji Hospital, ChinaNot recruiting
NCT04552379IFNβ1αStandard careSubcutaneousPontificia Universidad Catolica de ChileRecruiting
NCT04273763IFNα2βBromhexine Hydrochloride, Abidol hydrochloride and Standard careAtomization (nasal spray)WanBangDe Pharmaceuticals, ChinaNot recruiting
NCT04291729IFNα2Danoprevir/Ritonavir Spray inhalationThe Ninth Hospital of Nanchang, ChinaCompleted
NCT04251871IFNαLopinavir/Ritonavir or Traditional Chinese MedicinesAerosol inhalationBeijing 302 Hospital, ChinaRecruiting
NCT04275388IFNαLopinavir/Ritonavir and Abidor HydrochlorideNebulization inhalationJiangxi Qingfeng Pharmaceutical Co. Ltd.Not recruiting
NCT04469491IFNβ1βStandard careNebulization inhalationCentre Hospitalier Universitaire, AmiensSuspended
$ Data obtained from the WHO COVID-19 Vaccine website [1]. * status date was current as of 3 January 2021. # some studies involve “Standard care”, which includes treatment with/without antibiotics, corticosteroids or hydroxychloroquine and oxygen support, in addition to IFN-I therapy. ChiCTR—Chinese Clinical Trial Registry; IRCT—Iranian Registry of Clinical Trials; RECOVERY—Randomized Evaluation of COVID-19 Therapy; DisCoVeRy—Trial of Treatments for COVID-19 in Hospitalized Adults; NCT—National Clinical Trial.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Subbian, S. The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities. J. Respir. 2021, 1, 49-59. https://doi.org/10.3390/jor1010005

AMA Style

Subbian S. The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities. Journal of Respiration. 2021; 1(1):49-59. https://doi.org/10.3390/jor1010005

Chicago/Turabian Style

Subbian, Selvakumar. 2021. "The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities" Journal of Respiration 1, no. 1: 49-59. https://doi.org/10.3390/jor1010005

Article Metrics

Back to TopTop